Emapalumab is a Monoclonal Antibody owned by Swedish Orphan Biovitrum, and is involved in 7 clinical trials, of which 3 were completed, 3 are ongoing, and 1 is planned.

Emapalumab (NI-0501) is a monoclonal antibody that binds to soluble and receptor-bound forms of IFNγ. Binding to IFNγ neutralizes its activity, blocking its intracellular signaling to inhibit macrophage activation and the downstream release of proinflammatory cytokines. Emapalumab reduces the plasma concentrations of CXCL9, a chemokine induced by IFNγ.

The revenue for Emapalumab is expected to reach a total of $4.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Emapalumab NPV Report.

Emapalumab was originated by Light Chain Bioscience and is currently owned by Swedish Orphan Biovitrum.

Emapalumab Overview

Emapalumab (Gamifant) is a monoclonal antibody, acts as an immunosuppressant. It is formulated as injectable solution for intravenous route of administration. Gamifant is indicated for the treatment of primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional hemophagocytic lymphohistiocytosis therapy in pediatric (new born and older) and adult patients.

Emapalumab (NI-0501, Gamifant) is under development for the treatment of macrophage activation syndrome (MAS) in Still's disease and systemic lupus erythematosus (SLE), auto-immune and inflammatory diseases such as secondary hemophagocytic lymphohistiocytosis (HLH) and hyper-inflammatory syndrome, a complications associated with severe COVID-19 disease and It is administered intravenously. The drug candidate acts by targeting interferon gamma. It was under development for the treatment of primary HLH.

Emapalumab was under development for prevention of graft failure following hematopoietic stem cell transplantation and Graft failure.

Swedish Orphan Biovitrum Overview

Swedish Orphan Biovitrum (Sobi) is an integrated biopharmaceutical company. It focuses on the development of products for the treatment of a few rare diseases. The company specializes in biotechnology with prime capabilities in protein biochemistry and biologics manufacturing. Its product portfolio focuses on hemophilia, immunology, specialty care, inflammation and genetic and metabolic diseases. The company also provides innovative treatment for conditions such as amyotrophic lateral sclerosis (ALS) and Hemophilia A. Sobi also manufactures and markets specialty products for rare diseases for partner companies. The company has operational presence in Europe, the Middle East, North America, Russia, and Asia. Sobi is headquartered in Stockholm, Sweden.

The company reported revenues of (Swedish Krona) SEK15,529 million for the fiscal year ended December 2021 (FY2021), an increase of 1.8% over FY2020. In FY2021, the company’s operating margin was 24%, compared to an operating margin of 31.6% in FY2020. In FY2021, the company recorded a net margin of 17.3%, compared to a net margin of 21.3% in FY2020. The company reported revenues of SEK3,999 million for the third quarter ended September 2022, an increase of 3.2% over the previous quarter.

Quick View – Emapalumab

Report Segments
  • Innovator (NME)
Drug Name
  • Emapalumab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Hematological Disorders
  • Immunology
  • Infectious Disease
  • Musculoskeletal Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.